Scleroderma

Disease

Related News

CRISPR Therapeutics says CASGEVY momentum is building as zugo-cel and other pipeline data near

May 16, 2026

CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.

Vie Ventures Names Jeff Bluestone, PhD, as Managing Director

Feb 19, 2026

Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.